Skip to main content
. 2018 May 30;59(1 Suppl 1):E1–E86. [Article in Italian]

Tab. II.

Trial GQM05. Principali data set di analisi di efficacia e immunogenicità [11].

VGT
n (%)
Placebo
n (%)
TIV1
n (%)
TIV2
n (%)
Numero di soggetti randomizzati 2.721 2.715 183 186
FASE (Full Analysis Set Efficacy) 2.584 (95,0) 2.591 (95,4) NA NA
PPE (Per Protocol analysis set Efficacy) 2.489 (91,5) 2.491 (91,7) NA NA
PPI (Per Protocol analysis for Immunogenicity) 300 (81,7) 308 (84,6) 152 (83,1) 168 (90,3)